Although a separation between the AD patient and the HC subject was observed, an asymptote with a plateau after injection, as seen with other [18F]-labeled tau imaging agents, was not observed (Xia et al., 2013; Betthauser et al., 2019). This evidence concerns the gene MAPT and Alzheimer disease.